Tempo Therapeutics, Inc. is a clinical-stage technology company pioneering innovations in tissue engineering and regenerative medicine. The company’s Microporous-Annealed-Particle (MAP) technology platform enables the creation of synthetic tissue scaffolds designed to promote native tissue regeneration, reduce scarring, and improve outcomes across a wide range of surgical procedures. Tempo’s lead products, TT101 and TT108, target complex surgical sites and fascial incision reinforcement, positioning the company to address significant unmet clinical needs in surgical reconstruction.
Tempo completed a $12 million Series A financing round, led by Galaxy-Sirius Partners and Johnson & Johnson Innovation – JJDC, Inc., to advance its MAP-based scaffolds into the first-ever clinical trials. Martin Sands of Galaxy-Sirius Partners, led the round, highlighted the company’s potential: “Tempo is at the forefront of transforming medical outcomes through a genuine regenerative medical technology breakthrough. Tempo has a platform patented technology that can meaningfully alter the medical outcomes of a significant amount of surgical procedures… Tempo is at a pivotal time in their development as they pursue human clinical testing. If the application stimulates growth of native, natural, regenerated tissue instead of weak scar tissue, this is going to generate a great deal of momentum and attention.”
With this funding, Tempo is poised to establish the safety and effectiveness of its lead products in clinical trials, creating the foundation for a revolutionary approach to regenerative medicine. By leveraging MAP technology, the company aims to redefine surgical outcomes and bring scalable, next-generation biomaterials to patients in need.
